查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018297

Dasatinib市場規模、佔有率和趨勢分析報告：按藥物類型、適應症、分銷管道、地區和細分市場預測（2026-2033 年）

Dasatinib Market Size, Share & Trends Analysis Report By Drug Type, (Branded, Generic), By Indication (Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)), By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Dasatinib市場概況

預計到 2025 年，全球Dasatinib市場價值為 55.9 億美元，預計到 2033 年將達到 75.7 億美元，2026 年至 2033 年的複合年成長率為 4.27%。

由於骨髓惡性腫瘤（尤其是慢性骨髓性白血病和費城染色體陽性急性淋巴性白血病）的盛行率不斷上升，全球Dasatinib市場正在擴張。

標靶癌症治療的日益普及，使得已開發國家和新興國家都能更準確地診斷癌症，並儘早開始治療。醫生傾向於使用蛋白酪氨酸激酶抑制劑來持續控制病情，這支撐了藥物的長期需求。存活期的延長增加了藥物的累積使用量，並增強了藥物的收入前景。例如，OncLive在2025年11月報道稱， 非專利處方藥Dasatinib替尼學名藥的簡化新藥申請（ANDA）：20毫克、50毫克、70毫克、80毫克、100毫克和140毫克。該藥最初於2006年核准核准，並於2019年1月根據一項涉及78名兒童患者的II期臨床試驗結果，擴大了其適應症。本試驗中，3年無事件存活率為64.1%（95%信賴區間：52.4%–74.7%），誘導治療時髓株原細胞低於5%的患者比例為96%，強化治療時為97%。 81例患者中，4%發生致命性不利事件，10%停止治療。

精準醫學和分子診斷技術的進步增強了基於生物標記的治療方法選擇，並加速了Dasatinib等標靶治療的應用。抗藥性或不耐受慢性骨髓性白血病的臨床證據增強了醫生的信心，並支持了第二代蛋白酪氨酸激酶抑制劑的指引建議。例如，2026年1月，《癌症報告》（Cancer Reports）發表了一項回顧性分析，納入了2002年至2025年間接受低劑量Dasatinib（50 mg/天）治療的53名成年患者（中位年齡50歲）。分子學反應結果顯示，41.5%的患者達到MR4.5，20.8%的患者達到MR4.0，15.1%的患者達到主要分子學反應但未達到深度反應。 32.1%的患者存在蛋白酪氨酸激酶結構域突變，49.1%的患者發生了具有臨床意義的不利事件。此外，22.6%的患者因療效不佳而需要更換藥物，7.5%的患者因耐受性差而需要更換藥物。基準BCR-ABL1水準≥100%、T315I突變及高ELTS風險是預後不良的預測因子。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：Dasatinib市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：Dasatinib市場：按藥物類型分類的商業分析

  • 按藥物類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按藥物類型分類，2021-2033 年
  • 品牌商品
  • 非專利的

第5章：Dasatinib市場：按適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 慢性骨髓性白血病（CML）
  • 急性淋巴性白血病（ALL）

第6章：Dasatinib市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 專業癌症藥房

第7章：Dasatinib市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz Group AG
    • Sun Pharmaceutical Industries Limited
    • Hetero Drugs Limited
    • Aurobindo Pharma Limited
    • Dr. Reddy's Laboratories Limited
    • Intas Pharmaceuticals Ltd.
    • Cipla Limited
    • Lupin Limited
Product Code: GVR-4-68040-865-7

Dasatinib Market Summary

The global dasatinib market size was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, growing at a CAGR of 4.27% from 2026 to 2033. The global dasatinib market is expanding due to the rising prevalence of hematologic malignancies, particularly chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.

Increasing awareness of targeted oncology therapies has improved diagnosis and early treatment initiation across developed and emerging regions. Physicians prefer tyrosine kinase inhibitors for sustained disease control, supporting long term demand. Longer survival has increased cumulative drug utilization, strengthening revenue visibility. For instance, November 2025, OncLive reported FDA approval of a generic dasatinib abbreviated new drug application in six strengths, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Initial clearance occurred in 2006, with expansion in January 2019 based on a phase 2 trial in 78 pediatric patients showing 64.1 percent 3 year event free survival, 95 percent confidence interval 52.4 percent to 74.7 percent, 96 percent below 5 percent marrow blasts at induction, 97 percent at consolidation, 4 percent fatal adverse effects among 81 patients, and 10 percent discontinuation.

Advancements in precision medicine and molecular diagnostics have strengthened biomarker driven therapy selection, accelerating adoption of targeted treatments such as dasatinib. Clinical evidence in resistant or intolerant chronic myeloid leukemia has reinforced physician confidence and supported guideline recommendations for second generation tyrosine kinase inhibitors. For instance, January 2026, Cancer Reports published a retrospective analysis of 53 adults treated with low dose dasatinib 50 mg daily between 2002 and 2025, with a median age of 50 years. Molecular response outcomes included 41.5 percent achieving MR4.5, 20.8 percent MR4.0, and 15.1 percent major molecular response without deep response. Tyrosine kinase domain mutations were present in 32.1 percent, clinically significant adverse events in 49.1 percent, 22.6 percent required switching for inadequate response, and 7.5 percent for intolerance. Baseline BCR ABL1 greater than or equal to 100 percent, T315I mutation, and high ELTS risk predicted poorer outcomes.

Global Dasatinib Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dasatinib market report based on drug type, indication, distribution channel, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Myeloid Leukemia (CML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Oncology Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Type
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dasatinib Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dasatinib Market: Drug Type Business Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 5. Dasatinib Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Chronic Myeloid Leukemia (CML)
    • 5.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
  • 5.5. Acute Lymphoblastic Leukemia (ALL)
    • 5.5.1. Acute Lymphoblastic Leukemia (ALL) Market, 2021 - 2033 (USD Million)

Chapter 6. Dasatinib Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.7. Specialty Oncology Pharmacies
    • 6.7.1. Specialty Oncology Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Dasatinib Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Dasatinib Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Dasatinib Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bristol-Myers Squibb Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Teva Pharmaceutical Industries Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz Group AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Sun Pharmaceutical Industries Limited
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Hetero Drugs Limited
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Aurobindo Pharma Limited
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Dr. Reddy's Laboratories Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Intas Pharmaceuticals Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Cipla Limited
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Lupin Limited
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global dasatinib market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 5 Global dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 9 North America dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 10 North America dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 12 U.S. dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 15 Canada dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 16 Canada dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 18 Mexico dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Mexico dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 22 Europe dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Europe dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 25 UK dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 26 UK dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 28 Germany dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Germany dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 31 France dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 32 France dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 34 Italy dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 35 Italy dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 37 Spain dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Spain dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 40 Norway dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 41 Norway dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 43 Denmark dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Denmark dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 46 Sweden dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 47 Sweden dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 53 Japan dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 54 Japan dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 56 China dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 57 China dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 59 India dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 60 India dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 62 Australia dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 63 Australia dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 65 South Korea dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 66 South Korea dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 68 Thailand dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Thailand dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 72 Latin America dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 73 Latin America dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 75 Brazil dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 76 Brazil dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 78 Argentina dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 79 Argentina dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa dasatinib market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 85 South Africa dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 86 South Africa dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 91 UAE dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 92 UAE dasatinib market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait dasatinib market, by drug type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait dasatinib market, by indication, 2021 - 2033 (USD Million)
  • Table 95 Kuwait dasatinib market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dasatinib market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Dasatinib market dynamics
  • Fig. 11 Dasatinib market: Porter's five forces analysis
  • Fig. 12 Dasatinib market: PESTLE analysis
  • Fig. 13 Drug type market, 2021 - 2033 (USD Million)
  • Fig. 14 Branded market, 2021 - 2033 (USD Million)
  • Fig. 15 Generic market, 2021 - 2033 (USD Million)
  • Fig. 16 Indication market, 2021 - 2033 (USD Million)
  • Fig. 17 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
  • Fig. 18 Acute Lymphoblastic Leukemia (ALL) market, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 21 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Specialty oncology pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Dasatinib market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Dasatinib market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework